Hoth Therapeutics to Revise Financial Statements Due to Auditing Errors

Dow Jones

2025/03/26

By Sabela Ojea

Hoth Therapeutics will restate seven of its audited reports after it identified errors related to the recording of prepaid research and development costs.

The clinical-stage biopharmaceutical company on Tuesday said the audit committee of its board of directors took the decision of correcting the errors for each of its interim periods that ended March 31, June 30, and Sept. 30 for 2023 and 2024, and the 2023 annual report.

The company will disclose in its annual report for 2024 the restated audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods, the company said in a filing with the Securities and Exchange Commission.

"As a result, the audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods should no longer be relied on," the company said in a Securites and Exchange Comission filing.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

March 25, 2025 19:06 ET (23:06 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2522674832"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522674832\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522674832?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 07:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522674832","market":"us","top_or_hot":-1,"title":"Hoth Therapeutics to Revise Financial Statements Due to Auditing Errors","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> will restate seven of its audited reports after it identified errors related to the recording of prepaid research and development costs. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Tuesday said the audit committee of its board of directors took the decision of correcting the errors for each of its interim periods that ended March 31, June 30, and Sept. 30 for 2023 and 2024, and the 2023 annual report. \n</p>\n<p>\n  The company will disclose in its annual report for 2024 the restated audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods, the company said in a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  \"As a result, the audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods should no longer be relied on,\" the company said in a Securites and Exchange Comission filing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics to Revise Financial Statements Due to Auditing Errors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics to Revise Financial Statements Due to Auditing Errors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-26 07:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> will restate seven of its audited reports after it identified errors related to the recording of prepaid research and development costs. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Tuesday said the audit committee of its board of directors took the decision of correcting the errors for each of its interim periods that ended March 31, June 30, and Sept. 30 for 2023 and 2024, and the 2023 annual report. \n</p>\n<p>\n  The company will disclose in its annual report for 2024 the restated audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods, the company said in a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  \"As a result, the audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods should no longer be relied on,\" the company said in a Securites and Exchange Comission filing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522674832","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522674832","pubTimestamp":1742943960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hoth Therapeutics will restate seven of its audited reports after it identified errors related to the recording of prepaid research and development costs.The clinical-stage biopharmaceutical company on Tuesday said the audit committee of its board of directors took the decision of correcting the errors for each of its interim periods that ended March 31, June 30, and Sept. 30 for 2023 and 2024, and the 2023 annual report.The company will disclose in its annual report for 2024 the restated audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods, the company said in a filing with the Securities and Exchange Commission.\"As a result, the audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods should no longer be relied on,\" the company said in a Securites and Exchange Comission filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics因审计错误将修改财务报表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1},"content_text":"By Sabela Ojea \n\n\n \n\n\nHoth Therapeutics will restate seven of its audited reports after it identified errors related to the recording of prepaid research and development costs. \n\n\n  The clinical-stage biopharmaceutical company on Tuesday said the audit committee of its board of directors took the decision of correcting the errors for each of its interim periods that ended March 31, June 30, and Sept. 30 for 2023 and 2024, and the 2023 annual report. \n\n\n  The company will disclose in its annual report for 2024 the restated audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods, the company said in a filing with the Securities and Exchange Commission. \n\n\n  \"As a result, the audited consolidated and unaudited condensed consolidated financial statements for each of the non-reliance periods should no longer be relied on,\" the company said in a Securites and Exchange Comission filing. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 19:06 ET (23:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}